Drug Trial Radar · NCT03347422
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
Last checked: Nov 20, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Mar 17, 2018
Primary completion
Dec 3, 2021
Study completion Dec 3, 2021
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with primary CAD.
Conditions
- Cold Agglutinin Disease
Interventions
sutimlimab (BIVV009)Drug
Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
placeboDrug
Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants With Response to TreatmentTime frame: From Week 5 through Week 26
- Part B: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Part B, 6.5 g cohort: From first dose (Week 26) up to 149 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 184); Part B, 7.5 g cohort: From first dose (Week 26) up to 137 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 172)
Locations
53 sites in 14 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates PC
Tucson, Arizona
USC/Keck School of Medicine
Los Angeles, California
Georgetown University Medical Center
Georgetown, District of Columbia
Cleveland Clinic Florida
Weston, Florida
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Montefiore Medical Center
New York, New York
New York Medical College at Westchester Medical Center
Valhalla, New York
East Carolina University
Greenville, North Carolina
Cleveland Clinic
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
UW Hospitals and Clinics
Madison, Wisconsin
USC Health Clinics
Buderim, Queensland, Australia
Ballarat Oncology & Haematology
Ballarat, Victoria, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Perth Blood Institute
West Perth, Western Australia, Australia
Medical University of Vienna
Vienna, Austria
ZNA Stuivenberg
Antwerp, Belgium
University Hospitals Leuven
Leuven, Belgium
St. Michael's Hospital
Toronto, Ontario, Canada
McGill University Health Center
Montreal, Quebec, Canada
CHU d'Angers
Angers, France
Hôpital de Caen
Caen, France
Centre Hospitalier Henri Mondor
Créteil, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Gemeinschaftspraxis Hämatologie-Onkologie
Dresden, Germany
Universitätsklinikum Essen
Essen, Germany
Univ Ulm, Inst Klin. Transfusions. Immungen
Ulm, Germany
Hadassah Medical Center
Jerusalem, Israel
Laniado Hospital
Netanya, Israel
A. O. Spedali Civili di Brescia
Brescia, Italy
Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
U.O.C. Ematologia- Policlinico "A. Gemelli"
Rome, Italy
U.O.C. Ematologia Ospedale San Bortolo
Vicenza, Italy
Aichi Medical University Hospital
Nagakute, Japan
Japanese Red Cross Society Himeji Hospital
Himeji, Hyōgo, Japan
Ishikawa Prefectural Central Hospital
Kanazawa, Ishikawa-ken, Japan
Tokai University Hospital
Isehara, Kanagawa, Japan
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.